Regeneron Pharmaceuticals EV/EBIT REGN
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.
- Today, Nov 3, 2026
- 18.8×
- 10-year median
- 17.3×
- Against its 10-year history
- 62nd
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 6.4× to 38.0×
- Peer median
- 19.2×
Regeneron Pharmaceuticals' EV/EBIT is 18.8× as of Nov 3, 2026.
That is above its ten-year median of 17.3×, close to the middle of its last ten years.
Over that time it ranged from 6.4× in Jun 2022 to 38.0× in Jun 2017.
The median for 9 biotech stocks of a similar size is 19.2×.
EV/EBIT over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 18.8× | 15.8× | 21.9× |
| 2025 | 20.6× | 12.2× | 20.6× |
| 2024 | 17.7× | 17.4× | 31.8× |
| 2023 | 20.8× | 11.4× | 20.8× |
| 2022 | 11.4× | 6.4× | 12.2× |
| 2021 | 8.6× | 8.3× | 18.3× |
| 2020 | 16.4× | 15.5× | 28.5× |
| 2019 | 17.2× | 12.1× | 19.1× |
| 2018 | 16.0× | 13.8× | 21.6× |
| 2017 | 21.0× | 20.9× | 38.0× |
| 2016 | 31.0× | 27.1× | 41.0× |
| 2015 | 45.3× | 44.6× | 62.1× |
| 2014 | 50.6× | 34.9× | 52.4× |
| 2013 | 39.6× | 34.1× | 65.6× |
| 2012 | 60.9× | 51.2× | 65.5× |
Against its peers
Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.
| Company | EV/EBIT |
|---|---|
| REGNRegeneron Pharmaceuticals | 18.8× |
| VRTXVertex Pharmaceuticals | 28.1× |
| ONCBeOne Medicines | 40.2× |
| UTHRUnited Therapeutics | 16.3× |
| INCYIncyte | 28.3× |
| ALNYAlnylam Pharmaceuticals | 19.2× |
| EXELExelixis | 16.8× |
| NBIXNeurocrine Biosciences | 18.6× |
| HALOHalozyme Therapeutics | 17.8× |
| TECHBIO-TECHNE | 45.0× |
| Peer median | 19.2× |
Where Regeneron Pharmaceuticals ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Regeneron Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.